David Gailani, MD

Professor
Vanderbilt University Medical Center
Nashville, Tennessee, United States

David Gailani, MD is Professor of Pathology, Microbiology, and Immunology and medical director of the Clinical Coagulation Laboratory at Vanderbilt University Medical Center, Nashville, Tennessee, USA. His research laboratory studies the biology and pathology of the plasma contact activation system, and investigates methods to inhibit components of this system to produce therapeutic antithrombotic and anti-inflammatory effects.

Presentation(s):

• OC 41.3 - Intramolecular interactions that stabilize factor XII in a closed form

  Monday, June 26, 2023
  15:15 – 15:30 ET

• OC 49.2 - Pharmacological targeting of the contact pathway attenuates experimental autoimmune encephalomyelitis in mice

  Monday, June 26, 2023
  15:00 – 15:15 ET

• SSC 18.4 - Lessons from Titanium: comparing thrombogenic materials by surface area.

  Monday, June 26, 2023
  17:15 – 17:35 ET

• PB0535 - Development of function-blocking antibodies to plasma prekallikrein for the study of the interplay between coagulation and inflammation

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0566 - Prediction and validation of the effects of targeting either coagulation FXI activation or activity on thrombin generation

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0588 - Epitope Mapping of the α-FXIIa Allosteric Inhibitor Monoclonal Antibody 5C12

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0591 - Alphafold AI based applications explored as tools for predicting contact proteins PK, FXI and HK structure and evolutionary relationships

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0592 - Evaluation of the Role of Skeletal Muscle Myosin as a Cofactor for Factor XI Activation of Factor XII

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0700 - FXI inhibitor safety in hemophilia patients: computational prediction of thrombin generation.

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0705 - Pharmacological inhibition of coagulation factor XI reduces thromboinflammation in a nonhuman primate model of early atherosclerosis

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0706 - Mechanism by which coagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivo

  Monday, June 26, 2023
  18:30 – 19:30 ET

• OC 70.3 - Effect of High-Molecular-Weight Kininogen Binding to Factor XI and Prekallikrein on Thrombosis

  Wednesday, June 28, 2023
  10:45 – 11:00 ET

• OC 78.2 - Activation of coagulation factor XII by bacterial lipopolysaccharides

  Wednesday, June 28, 2023
  10:30 – 10:45 ET